CN Mobile Logo

Search form


Prostate Cancer

Prostate Cancer

Androgen deprivation therapy (ADT), a mainstay of treatment for men with prostate cancer, may raise the risk of dementia, according to a new study.

Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases (liver and lung) fare better with the androgen receptor inhibitor enzalutamide than placebo, according to a new analysis from the phase III AFFIRM trial.

Men who have vasectomies do not have a higher risk of prostate cancer and are not more likely to die from the disease, according to a large, prospective study.

While survival at 10 years was nearly identical (close to 99%), a new study found that localized prostate cancer is more likely to metastasize in men receiving active surveillance compared with those who have surgery or radiation therapy.

A 66-year-old Caucasian man with a history of hypertension, hyperlipidemia, and rheumatoid arthritis was diagnosed with prostate cancer.

PSA failure in men with localized, intermediate- or high-risk prostate cancer was associated with increased all-cause mortality in only those patients with no or minimal comorbidity.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.